Aims/hypothesis. Serum anti-CD38 autoantibodies (aAbs) have been reported in 17 to 19% of patients with long-standing Type I (insulin-dependent) diabetes mellitus and Type II (non-insulin-dependent) diabetes mellitus. Whether these aAbs are also found in new-onset Type I diabetes and in Latent Autoimmune Diabetes in Adults (LADA) is not known, as is their relationship with conventional islet aAbs. Methods. These issues were addressed by studying new-onset Type I and LADA diabetic cohorts with a recently developed anti-CD38 enzymatic immunoassay. Results. Anti-CD38 aAb prevalence among newonset Type I patients (3.8%) was lower than previously found in long-standing Type I diabetes (11.7%, as defined with the 97.5 percentile cutoff; p=0.01), suggesting a late appearance of these aAbs. Among LADA patients, 14.9% were anti-CD38 + . Anti-CD38 were only associated with anti-GAD aAbs in newonset Type I diabetes. Although the CD38 target molecule was expressed in human pancreatic islets, anti-CD38 aAbs did not contribute to the islet cell antibody (ICA) immunofluorescence reactivity. All the positive sera analysed for Ca 2+ release were found to mobilise it. In agreement with these agonistic features, anti-CD38 + new-onset Type I patients showed higher fasting C-peptide values as compared to negative counterparts; the association was stronger when the analysis was limited to the agonistic anti-CD38 + sera. A similar trend was found among LADA patients. Conclusion/interpretation. Anti-CD38 aAbs are distinct markers of islet autoimmunity which are more prevalent in long-standing disease, as opposed to the other known islet aAbs. Their in vitro agonistic properties could be operating in vivo as well, as they identify sub-groups of patients with higher residual betacell function. [Diabetologia (2002[Diabetologia ( ) 45:1667[Diabetologia ( -1677 
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Damage to the beta cell is one of the crucial events leading to diabetes. Whether this damage occurs by autoimmune mechanisms, as in Type I (insulin-dependent) diabetes mellitus [1] , or by other less defined phenomena (e.g., glucose toxicity [2] , lipotoxicity [3] , prolonged excessive insulin secretion [4] ), as in Type II (non-insulin-dependent) diabetes mellitus [5] , the final result is impaired insulin secretion [6] . A number of autoantibodies (aAbs) marking the immune-mediated destruction of the beta cell typical of Type I diabetes have been described since the identification of islet cell antibodies (ICA) [7] . ICA comprise a number of autoreactive immunoglobulins with different target antigens, one of which has later been identified as GAD [8, 9] . As for ICA, anti-GAD reactivity is higher at diagnosis but, unlike ICA, it persists for a long time in sera, thus achieving high sensitivity in identifying diabetic patients [10] . Anti-IA-2 aAbs are responsible for another major subfraction of the ICA reactivity [8, 11] and, together with anti-GAD aAbs, they account for about 90% of ICA immunofluorescence [8] . Anti-IA-2 aAbs are an early marker of islet autoimmunity, being mainly found at disease onset [8, 11] ; they are also found with higher frequency in younger patients [12] independently of disease duration [13] , probably reflecting a severe beta-cell destruction leading to the clinical onset of the disease early in life [14, 15, 16, 17] . Although these markers are mainly found in Type I diabetic patients, a subgroup of patients routinely classified as Type II was also found to show high prevalences of ICA and anti-GAD, but not of anti-IA-2 aAbs. These patients have later been classified as having a slow progressive form of Type I diabetes, defined as Latent Autoimmune Diabetes of the Adult (LADA) [12, 13, 18, 19, 20, 21, 22] .
Anti-CD38 aAbs have been described as new markers of beta-cell autoimmunity [23, 24, 25] . The CD38 target molecule is a membrane glycoprotein mainly expressed in the haematological compartment, functioning as a signalling receptor and an ectoenzyme capable of producing and degrading cyclic ADP-ribose (cADPR), a Ca 2+ -mobilising second messenger [26, 27] . cADPR produced by CD38 has been implicated in the mechanisms of insulin secretion in rodents [28, 29] . We have recently developed an anti-CD38 enzymatic immuno-assay, suitable for screening large cohorts of patients [25] . With this approach, prevalences of 19.1% and 16.7% were found among Caucasian Type I and Type II diabetic subjects with long-standing disease, respectively [25] . The majority of these aAbs showed agonistic properties, capable of triggering Ca 2+ release from CD38 + target cells [25] . Anti-CD38 + sera incubated with purified islet cells induced not only Ca 2+ mobilisation, but also insulin secretion, with a direct correlation between the two effects [24, 30] . In agreement with these experimental findings, anti-CD38 + Type II diabetic patients were characterized by higher residual beta-cell function and higher BMI, i.e., a phenotype opposite to that of LADA [25] .
On these grounds, we aimed to answer three critical questions: (i) are anti-CD38 aAbs more prevalent at Type I diabetes onset than in late stage disease like the other known islet aAbs (ii) despite the phenotype opposite to that of LADA observed in anti-CD38 + Type II patients [25] , are anti-CD38 aAbs also found among LADA subjects (iii) what is the relationship, if any, between anti-CD38 aAbs and the conventional markers of beta-cell autoimmunity. These issues were addressed by studying a large cohort of newly diagnosed Type I diabetic patients and a smaller group of LADA patients. Comparisons between anti-CD38 and the other islet aAbs were also carried out, both in these study cohorts and in a previously characterised group of long-standing Type I diabetic subjects [25] .
Subjects and methods
Patients. We recruited 188 Caucasian new-onset Type I diabetic subjects from patients identified by the population-based registry of the province of Torino [31] . Blood samples were obtained within two months after onset. Diagnosis of Type I diabetes was made according to the American Diabetes Association and WHO criteria [32, 33] . We selected 67 Caucasian LADA subjects with the following inclusion criteria: age more than 30 years old at diagnosis, no ketoacidosis at onset and absence of insulin therapy in the first 6 months after diagnosis, positivity of either anti-GAD or ICA. Exclusion criteria were secondary forms of diabetes and a history of previous interferon therapy. Healthy control subjects with no family history of diabetes, normal fasting plasma glucose and similar sex and age distribution were selected at the local blood bank and at the Department of Paediatrics among children undergoing minor elective surgical procedures. All blood samples were obtained in the morning after overnight fasting. Sera were divided in aliquots and stored at -80°C until analysis. A cohort of Type I diabetic patients previously characterised for anti-CD38 titres [25] was also included and assayed for islet aAbs for comparative analyses. Informed consent was obtained from each participant and the study was approved by the Hospital Review Board and Ethics Committee.
Enzymatic immuno-assay for anti-CD38 aAbs. Anti-CD38 aAb titres were measured with an enzymatic immuno-assay (EIA), using recombinant soluble CD38 (rsCD38, made available by H. C. Lee, University of Minnesota, Minneapolis, Minn., USA) [34] as the immobilised target antigen [25] . The anti-CD38 EIA was previously shown to have a consistent reproducibility (4.3% intra-assay and 11.6% inter-assay variability) [25] . EIA plates were coated with rsCD38 and subsequently saturated with 5% non-fat dry milk in PBS. Sera of patients diluted 1:3,000 were added and incubated for 2 h at 37°C. This dilution was chosen as the one effectively differentiating between positive and negative samples, as compared with the 1:640 previously used [25] , minimising aspecific binding to the EIA plate; the previously characterised cohort of Type I patients was also reanalysed at this higher dilution. After washing, an alkaline phosphatase-conjugated anti-human Ig monoclonal antibody (mAb) (Sigma, St. Louis, Mo., USA) was added; no difference was observed when this was substituted by an anti-human IgG mAb. The reaction was visualised with paranitrophenylphosphate chromogen and reading of the absorbance at 405 nm after 45 min. Each sample was assayed in triplicate in at least two different experiments and the mean of these six measurements was used for all subsequent calculations. A standard curve was derived from a highly reactive serum in each experiment: the optical density (OD) obtained with this serum was conventionally defined as equal to 10000 arbitrary units (AU/ml) and the reactivity of the other samples calculated in proportion with the following formula:
where the negative control was obtained by incubation of the immobilised rsCD38 with secondary mAb alone. The upper limit of the normal range was defined as the 97.5 centile of the anti-CD38 titres measured in the sera of 358 control healthy subjects (median age 17, range 0-95 years). This percentile was chosen as the one effectively differentiating between diabetic patients and control subjects; the cut-off value thus obtained was 6927 AU/ml. Each study group was compared with a cohort of healthy control subjects matched for age and sex.
Islet aAb assays. ICA were assayed by indirect immunofluorescence on frozen sections of human blood group 0 pancreas and positivity expressed in Juvenile Diabetes Foundation (JDF) units, by a standard curve based on the international JDF unit reference sample. An ICA titre more than or equal to five JDF units was considered as positive. In preadsorption experiments, sera were preincubated with saturating amounts (1 µg in 10 µl of each serum) of either rsCD38 or an irrelevant protein (HIV gp120; Chiron, Emeryville, Calif., USA) prior to ICA testing. Anti-GAD aAbs were measured by a radioligand assay using human recombinant GAD65 as the target antigen (RSR, Cardiff, UK) [35] . Sera were incubated with 125 I-labelled GAD65, followed by the addition of solid phase protein A to precipitate the labelled immune complexes; after centrifugation, supernatants were discarded and the precipitates counted for 125 I. Samples were classified as positive for anti-GAD titres more than or equal to 0.9 U/ml. Anti-IA-2 aAb titres were measured by a similar radioligand assay with the same procedure, using human recombinant IA-2 as the target antigen (RSR). A titre more than or equal to 0.75 U/ml was classified as positive. A 100% sensitivity and specificity in these three islet aAb assays was repeatedly achieved by our Laboratory in the Immunology of Diabetes Workshop Proficiency Programs.
Immunohistochemistry. Tissues were fixed in 10% buffered formalin and embedded in paraffin. Sections were collected on poly-L-lysine-treated slides, dewaxed, rehydrated and immersed in 3% H 2 O 2 to quench endogenous peroxidase activity. Slides were then immersed in 10 mmol/l sodium citrate buffer, pH 6.0, and heated three times for 3 min at high setting in a 750 W output microwave oven. An incubation for 15 min with an avidin-blocking reagent (Biogenex, San Ramon, Calif., USA) at room temperature was then done to prevent endogenous biotin reactivity. The slides were subsequently incubated for 30 min at room temperature with the AT1 anti-CD38 mAb (provided by J. Hilgers, BioProbe BV, Amstelveen, The Netherlands). The reaction was visualised with the Dako LSAB2 peroxidase kit (Dako, Glostrup, Denmark) and liquid H 2 O 2 -3-3′-diaminobenzidine (Sigma). In preadsorption experiments, the AT1 mAb was preincubated overnight at 4°C with saturating amounts of either rsCD38 or the gp120 irrelevant protein. For indirect immunofluorescence, frozen pancreatic tissue sections were reacted with IB4 (IgG 2a ), OKT10 (IgG 1 ), T16 (IgG 1 ; Immunotech, Marseille, France), HB7 (IgG 1 ) and AT1 (IgG 1 ) anti-CD38 mAbs followed by fluorescein isothiocyanate-or phycoerithrin-conjugated anti-mouse Ig secondary Ab. 2+ release. Analysis of Ca 2+ mobilisation mediated by anti-CD38 aAbs was carried out on the Jurkat T acute lymphoblastic leukaemia cell line [25] . Cells were loaded with Fluo 3-AM (Sigma), a Ca 2+ -sensitive fluorescent dye and subsequently incubated with 50 µl of serum. Effects on intracellular Ca 2+ concentration ([Ca 2+ ] i ) were continuously analysed at 37°C with a FACSort cytofluorimeter (Becton Dickinson, Milano, Italy). Controls included sera from diabetic patients negative by anti-CD38 EIA and cells treated with the 4-bromo A23187 ionophore (Sigma) to ensure proper Fluo 3-AM loading. Modifications over time of [Ca 2+ ] i were followed by continuously recording fluorescence shifts of Fluo 3-AM during a 5-min time-course; the extrapolated Fluo 3-AM mean fluorescence intensity was then used for numerical presentation of data. The cut-off was set at the value for which both sensitivity and specificity of the assay were of 100%.
Agonistic activity of anti-CD38 aAbs on Ca
Clinical and metabolic parameters. HbA 1c was measured by high-performance liquid chromatography. Fasting plasma C-peptide was measured by radioimmunoassay (DPC, Los Angeles, Calif., USA). The three therapy categories for LADA subjects (diet alone, oral hypoglycaemic agents and insulin, with or without oral hypoglycaemic agents) were considered mutually exclusive.
Statistical analysis.
Values are expressed as means ± SD or median (range), according to their distribution. Comparisons between proportions were made with the χ 2 test and Fisher's exact test, when appropriate. Comparisons of means between two groups were carried out with the Student's t test for normal distributed variables or with the Mann-Whitney U test for nonnormal variables. Analysis of data was done using Stata 7.0 (Stata Corporation, College Station, Tex., USA). Differences were considered statistically significant for p values less than or equal to 0.05.
Results
Characteristics of the patients. Clinical and anti-islet autoimmunity profiles of the 183 new-onset Type I diabetic patients studied are shown in Table 1 . Their [8, 36, 37, 38, 39, 40] . The characteristics of the 67 LADA patients studied are shown in Table 2 . Clinical and autoimmune characteristics of a long-standing Type I diabetic cohort previously characterised for anti-CD38 aAbs [25] are summarised in Table 3 . The prevalence of anti-CD38 + individuals in this group, as defined with the 97.5 percentile cutoff, was 11.7%.
Titres and prevalence of anti-CD38 aAbs among newonset Type I and LADA diabetic patients. Anti-CD38 aAb titres obtained for new-onset Type I diabetic subjects are shown in Fig. 1 . The distribution shows a continuous pattern spanning through all values; the majority of subjects (both diabetic and healthy) showed reactivities less than 2000 AU/ml. Among the 183 patients studied, 7 (3.8%) were above the cut-off value selected, whereas only 1 out of the 171 control subjects (0.6%) was characterised as anti-CD38 + (p=0.04). The prevalence observed in new-onset Type I patients was lower than the 11.7% found in a cohort of Type I diabetic patients with long-standing disease ( Anti-CD38 aAb titres obtained for LADA patients are shown in Fig. 2 . The prevalence of anti-CD38 + LADA patients was 10 out of 67, 14.9% as compared to 1.5% among the 66 control individuals (p=0.005). The prevalence obtained was not different to that observed in the previously studied cohorts of longstanding Type I diabetic patients (11.7%; Table 3 ) and Type II diabetic patients (17.5%, as defined with the 97.5 centile cut-off).
Comparison of anti-CD38 with other islet aAbs.
Comparative analyses of anti-CD38 with ICA, anti-GAD and anti-IA-2 aAbs were carried out in different diabetic groups (Fig. 3) . Positivity for anti-GAD aAbs was found with higher frequency among new-onset Type I patients who were anti-CD38 + as compared to negative counterparts (100% vs 63.9%; p=0.05). A trend towards higher frequencies of ICA among anti-CD38 + subjects was also observed in this group (83.3% vs 55.2%; p=0.18). Among patients with longstanding Type I diabetes, where the prevalence of islet aAbs is much lower, anti-CD38 aAbs were not more prevalent among subjects positive or negative for other islet aAbs. No relevant association was found in the LADA cohort. As anti-IA-2 aAbs have a very low prevalence and little additional diagnostic value in LADA patients, being mainly associated to ICA and anti-GAD, they were not assayed in this group.
Lack of contribution of the anti-CD38 aAb fraction to the ICA reactivity.
Among all the diabetic patients examined, only 37% of anti-CD38 + individuals were also ICA + . Given this rather incomplete overlapping ▲ between anti-CD38 aAbs and ICA, we investigated to further exclude any contribution of anti-CD38 aAbs to the ICA reactivity. To this aim, immunofluorescence for ICA on pancreatic tissue sections was carried out by preincubating different sera either with an irrelevant protein or with saturating amounts of rsCD38. As shown in Figure. 4, no difference in fluorescence intensity was evident when ICA + anti-CD38 + sera were preadsorbed with rsCD38 (Fig. 4, panel A, B) . The same fluorescence intensity was also highlighted when ICA + anti-CD38 -sera were used, either intact (Panel C) or preadsorbed with rsCD38 (Panel D). Preadsorption was indeed effective, since the procedure led to a consistent decrease in anti-CD38 reactivity in the anti-CD38 + sera, but not in the anti-CD38 -ones (Panel E). ICA -anti-CD38 + sera did not give any signal (data not shown).
To exclude that these findings could be due to lack of CD38 expression in the human pancreas, immunofluorescence with a wide panel of anti-CD38 murine mAbs was carried out, but none of them gave a signal strong enough to be visualised on the autofluorescent background characteristic of pancreatic tissue sections (data not shown). This issue was therefore addressed by immunohistochemistry (Fig. 5) : indeed, at low magnification (Panel A), islet cells were already visible as differentially stained by the AT1 mAb (anti-CD38). On the contrary, exocrine pancreatic structures did not show any reactivity. Panel B shows a single islet of Langerhans at higher magnification. The signal visualised was specific, since no reactivity was detected when the AT1 mAb was first preadsorbed with saturating amounts of rsCD38 (Fig. 6, Panel B) , as compared with the same mAb preincubated with an irrelevant protein (Panel A). 2+ release. Among the anti-CD38 + sera identified in new-onset Type I patients and LADA patients, 8 out of 17 (47.1%) anti-CD38 + samples for which sufficient serum was still available were analysed for their activity on Ca 2+ release. As shown in Fig. 7 , all the positive sera were capable of inducing Ca 2+ release when incubated with CD38 + Jurkat T cells, thus showing agonistic activity, as previously reported [25] . On the contrary, none of the 21 control antinumber of anti-CD38 + new-onset Type I diabetic patients identified (n=7), these individuals were characterised by borderline significantly higher fasting plasma C-peptide values as compared to negative counterparts [median 0.95 (range 0.14-2.97) vs 0.42 (0-5.70) ng/ml; p=0.05] (Table 4) . Interestingly, this association was more evident when the analysis was limited to the anti-CD38 + sera showing agonistic activity [1.14 (0.50-2.97) vs 0.43 (0-5.70) ng/ml; p=0.03].
Agonistic effect of anti-CD38 aAbs on Ca
Also in the LADA cohort, the positivity for anti-CD38 aAbs was associated with a trend towards higher fasting plasma C-peptide values [1.10 (0.08-5.98) vs 0.72 (0-3.84) ng/ml; p=0.35] (Table 5) . Also in this case, this trend was more effectively observed when only anti-CD38 + subjects showing agonistic aAbs were considered [1.62 (1.24-2.49) vs 0.72 (0-5.98); p=0.07]. 
Discussion
The significance of anti-CD38 aAbs as a marker of islet autoimmunity was addressed in this study by carrying out: (i) comparative analyses of anti-CD38 with conventional islet aAbs in different diabetic groups; (ii) in vitro functional studies of anti-CD38 aAbs and analysis of their associations with relevant clinical and metabolic parameters. Moreover, immunohistochemistry definitely showed that human pancreatic islets do express CD38, since previous reports only documented the presence of CD38 mRNA in this tissue, but not of the final protein product [41] . The fact that no signal was highlighted by immunofluorescence is probably due to the low epitopic density of pancreatic CD38, not enough to overwhelm the characteristic autofluorescence of this tissue [42, 43] . The overall body of data gathered indicates that anti-CD38 aAbs are new markers of beta-cell autoimmunity, characterised by their own unique features.
Besides showing an independent pattern of expression among different diabetic groups as compared to the conventional islet aAbs, preadsorption experiments also showed that, in contrast to anti-GAD and anti-IA-2 aAbs [8, 9, 11] , anti-CD38 reactivity does not contribute to ICA immunofluorescence. This point is relevant as there are patients who are positive only for ICA but for neither anti-GAD nor anti-IA-2 [12, 21] : this additional ICA subspecificity is not as yet defined, and it does not correspond to anti-CD38 as well. The finding that anti-CD38 aAbs are not an ICA subfraction is not surprising if a key difference in the epitopes recognised is considered. Indeed, the ICA immunofluorescence is located in the cytoplasm [44] , while CD38 is expressed on the cell surface; moreover, all the anti-CD38 aAbs selected so far recognize its extracellular portion, since the target rsCD38 used in our assay does not include the transmembrane and intracellular domains [34] .
The choice of a single cut-off for anti-CD38 positivity, defined as the 97.5 centile (6927 AU/ml) of the values obtained in a wide cohort of healthy subjects, gives the advantage of uniforming the selection of positive cases in different study groups, thus avoiding the common influence of age on aAb titres [45] . Interestingly, the previously reported association of anti-CD38 aAbs with higher residual beta-cell function in Type II diabetic patients [25] Moreover, the fact that the anti-CD38 prevalence among LADA subjects was not higher than among long-standing Type I diabetic patients and Type II diabetic patients also confirms that, despite the autoimmune features, the previously characterised anti-CD38 + Type II diabetic subgroup does not correspond to LADA, as suggested by the different phenotype (i.e., higher residual insulin secretion, higher BMI) [25] .
The precise diagnostic significance of anti-CD38 aAbs is still unclear. However, the observation that anti-CD38 aAbs were less prevalent at onset (3.8%) than in long-standing disease (11.7%) among Type I patients suggests that they could be a marker of a later stage of beta-cell destruction. In this respect, also the borderline association between anti-GAD and anti-CD38 aAbs in new-onset Type I diabetes could be due to the longer persistence of anti-GAD as compared to the other islet aAbs. In our previous work [25] , we did not find any correlation between anti-CD38 aAbs and disease duration among Type I diabetic patients, but the average long course of disease in that cohort made it difficult to address this issue. Despite the limit of the cross-sectional nature of this study, the increase in anti-CD38 prevalence with diabetes progression is of interest, since it represents a trend opposite to that of all the other islet aAbs, which show decreasing prevalences, although with different kinetics, as disease proceeds. However, longitudinal studies of Type I patients are needed to give a final answer to whether anti-CD38 arise at a later stage of beta-cell destruction.
The abundant expression of extra-pancreatic forms of CD38 could offer an explanation for the increase of anti-CD38 aAbs in long-standing disease. Indeed, islet aAbs commonly vanish a few years after the clinical onset of diabetes, when most beta cells have disappeared. Anti-GAD aAbs are the only exception, possibly because the GAD molecule is expressed also in nervous tissue, thus maintaining an antigenic trigger even after beta-cell failure; moreover, the short-lived aAbs can rapidly re-appear after islet transplantation [46] . A different time course of the primary immune trigger from the pancreas and subsequent persistence of antigenic stimuli from several tissues could justify the unique pattern of anti-CD38 aAbs.
Whether anti-CD38 aAbs are passive markers innocently witnessing beta-cell destruction or rather take an active part to the immune damage remains to be elucidated. Regarding this second possibility, the repeated observation that the vast preponderance of anti-CD38 aAbs are endowed with agonistic properties is appealing. Prolonged Ca 2+ influx in the beta cell is known to trigger several deleterious effects such as desensitisation [4] and apoptosis [47] . The large preponderance of agonistic features for anti-CD38 aAbs is also in line with the clinical and metabolic correlations observed. Indeed, the Ca 2+ -mobilising activity of anti-CD38 aAbs was shown not only to be effective in lymphocytic cell lines [25] , but also in purified human islets, where it is coupled to stimulation of insulin secretion [30] . In this scenario, the observed in vitro agonistic features of anti-CD38 aAbs could be operating in vivo as well. Besides being previously reported in Type II diabetes [25] , also anti-CD38 + subjects with new-onset Type I diabetes were characterised by higher fasting C-peptide values, and a stronger association was found when only agonistic anti-CD38 + sera were considered. A similar trend was also observed among LADA patients. Higher residual insulin secretion is a common trait when circulating anti-CD38 aAbs are found, with the only exception of long-standing Type I diabetes [25] , where, expectedly, no target beta-cells are left for triggering by anti-CD38 aAbs. Whether this stimulating effect would be really beneficial in the long-term is opinable: triggering of insulin secretion would be initially favourable in the insulinopenic setting of early diabetes, but sustained stimulation could also add a further challenge and possibly lead to faster exhaustion of the limited beta-cell resources.
In conclusion, anti-CD38 aAbs are distinct markers of beta-cell autoimmunity, not merely accompanying the other islet aAbs but possibly marking a later stage of Type I diabetes. Moreover, they not only modify the in vitro behaviour of cells by triggering Ca 2+ release and insulin secretion, but they could also affect the in vivo metabolic environment, since they identify subgroups of patients with better preserved beta-cell function. Longitudinal studies will further clarify the natural history of these aAbs and of their biological effects.
